

- 7 -

Claims

1. A blood plasma for human use pooled from donors which belong to 10 % or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing ~~substantial amounts of~~ blood or blood plasma of blood group O characterized in that

- ^{five}~~four~~ to ^{six}~~eight~~ parts of blood or blood plasma from donors having the blood group A,

- ~~more than three~~ ^{four} parts to ~~seven~~ ^{five} parts of blood or blood plasma from donors having the blood group B,

- zero to ^{one}~~two~~ parts of blood or blood plasma from donors having the blood group AB.

2. The blood plasma according to claim 1 virus-inactivated by any virus inactivation or virus removal method.

3. The blood plasma according to claim 2 wherein the blood plasma was inactivated by solvent/detergent treatment, irradiation, pasteurisation and/or nanofiltration.

4. The blood plasma according to claim 3 wherein the virus inactivation was performed by using detergents such as oxyethylated polyphenols, like Triton-X-100, and/or polyoxyethylene derivatives of fatty acids such as Tween 80 and tri-N-butylphosphate (TNBP), or combinations thereof.

5. The blood plasma according to claim 3 virus inactivated by treatment with long-chain fatty acids, such as caprylic acid or the respective salts.

6. The blood plasma according to any of the forgoing claims substantially free of virus inactivating agents.

- 8 -

7. The blood plasma of any one of the foregoing claims having ABO blood group specific antibody titre lower than 16 for anti-A and anti-B IgM antibodies, and lower than 64 for anti-A and anti-B IgG antibodies.
8. The blood plasma of any of the foregoing claims in liquid, frozen, dried, or lyophilised form.
9. A pharmaceutical composition comprising the blood plasma of any one of the claims 1 to 8.
10. Use of the blood plasma of any of the foregoing claims for the manufacturing of a medicament for the treatment of coagulation factor deficiencies, thrombotic purpura, and in repeated large volume plasma exchange.
11. A process for manufacturing the blood plasma of any one of the claims 1 to 8 by admixing
- four to eight parts of blood or blood plasma from donors having the blood group A,
 - more than three parts to seven parts of blood or blood plasma from donors having the blood group B,
 - zero to two parts of blood or blood plasma from donors having the blood group AB.